Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-04-03 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a regulatory milestone: the FDA granting Orphan Drug Designation to the drug rilzabrutinib for two rare diseases. It discusses clinical trial data, regulatory review status (FDA, EU, China for ITP), and provides general company information and forward-looking statements. This content is characteristic of an initial announcement of significant corporate or regulatory news, rather than a comprehensive financial report (10-K, IR) or a transcript (CT). Since it is a press release announcing a specific regulatory/development event, it fits best under the general category for regulatory announcements that aren't strictly financial results or formal filings. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing a regulatory action, although 'LTR' (Legal Proceedings Report) is sometimes used for regulatory actions, this is a positive announcement, not a legal proceeding. 'RNS' serves as the best general regulatory announcement category here.
2025-04-03 French
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Sanofi, under the Securities Exchange Act of 1934. It includes references to press releases dated March 28, 2025, which are attached as exhibits. The document length is short (1509 characters) and primarily serves as a report submission with attached press releases rather than containing substantive financial data or detailed reports. Form 6-K filings typically serve as periodic reports for foreign issuers to disclose material information, often including press releases or announcements. Given the short length and nature of the content, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often include such SEC filings like Form 6-K.
2025-04-02 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is explicitly titled "Disclosure of trading in own shares" and contains detailed tables showing the purchase of Sanofi's own shares over a specific period (24 March 2025 to 28 March 2025), including volume, price, and transaction references. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. Therefore, the appropriate filing type code is POS (Transaction in Own Shares).
2025-03-31 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' which translates to 'Declaration of transactions on own shares'. It details daily aggregated and individual transactions of the company's own shares, including volume, price, and market information. This is a report of the company's buyback or sale of its own shares. There is no indication of it being an announcement of a report or a certification. The content is specific to transactions in own shares, matching the description of the 'Transaction in Own Shares' category.
2025-03-31 French
Communiqué de presse : Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs
Earnings Release Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces the US FDA approval of a new drug, Qfitlia, for hemophilia treatment. It contains key financial/product highlights, quotes from management and external experts, clinical trial data summaries, and contact information for media and investors. This format strongly suggests an initial announcement of significant corporate news, specifically related to product milestones or financial performance highlights, rather than a comprehensive annual report (10-K), a detailed interim report (IR), or a transcript of a call (CT). Since it focuses on the immediate release of key results and regulatory news, it aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Given that this is a major product approval announcement, which often serves as the primary news release for the period, 'ER' (Earnings Release) is the most appropriate classification, as these releases frequently cover major operational/regulatory achievements alongside or instead of pure quarterly financials. It is not a short announcement pointing to another document, so RPA/RNS is less likely than ER. Q1 2025
2025-03-28 French
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces the FDA approval of a new therapy, Qfitlia, for hemophilia. It contains key financial/operational highlights (efficacy data, dosing frequency, pricing context) and quotes from management and external stakeholders. This structure—a concise announcement of a major event (FDA approval) with key data points—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a comprehensive annual report (10-K), a detailed interim report (IR), or a transcript (CT), and it focuses on the immediate release of significant news, 'Earnings Release' (ER) is the most appropriate classification, as these releases often cover major operational milestones alongside financial results, or in this case, a major regulatory milestone that impacts future revenue. It is not an RPA because it contains the substantive details of the approval and data, not just an announcement that a report is available.
2025-03-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.